Lilly’s experimental drug met endpoints for blood-sugar level reduction and weight loss at trial.
One of Eli Lilly & Co.’s most highly anticipated experimental medicines helped diabetic patients lose more weight than any drug currently on the market, underscoring its potential in the increasingly ...
Zacks Investment Research on MSN
LLY's next-gen obesity drug meets goal in first phase III study for T2D
Eli Lilly LLY announced positive top-line results from a late-stage study evaluating its experimental once-weekly weight-loss drug, retatrutide, in adults with type II diabetes (T2D) This study, ...
One of Los Angeles’s most architecturally significant mid-century homes is coming to the market next week for $11.9 million, Mansion Global has learned. Case Study House No. 18, also known as the West ...
A team of researchers from the IGTP and the IISPV has published a study in the scientific journal Inflammatory Bowel Diseases describing an experimental rat model that reproduces key features of ...
PORTLAND, Ore. (KOIN) – An Oregon Health & Science University study found an experimental shot “dramatically” reduced HIV levels and could lead to new treatments. This means people living with the ...
Impact of the COVID-19 Pandemic Mitigation Strategies on Cancer Treatment Trials: A Meta-Analysis of Industry and National Cancer Institute Studies This quasi-experimental study used data from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results